α glucosidase

α-Glucosidase (α-D-Glucosidase) is a carbohydrate hydrolyzing enzyme that catalyzes the release of α-glucose from the non-reducing end of the substrate, playing a vital role in glucose absorption by the small intestine. Inhibiting α-Glucosidase effectively manages non-insulin-dependent diabetes mellitus (NIDDM).

α-Glucosidase-IN-23 is an orally active inhibitor of α-glucosidase that can decrease blood glucose levels by inhibiting α-glucosidase (IC50 = 4.48 μM).

α-Glucosidase-IN-4 is a potent α-glucosidase inhibitor exhibiting antihypertensive and hypoglycemic activity.

α-Amylase/α-Glucosidase-IN-1 (compound 33) is an effective inhibitor of α-amylase and α-glucosidase, with IC50 values of 2.01 and 2.09 μM, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has potential anti-hyperglycemia properties [1].

α-Glucosidase-IN-8 (Compound 4k) is a potent competitive inhibitor of α-glucosidase with an impressive IC50 value of 0.18 μg/mL [1].

α-Glucosidase-IN-9 (compound 7) is a highly potent α-glucosidase inhibitor with an IC50 of 55.6 μM, suitable for type II diabetes research [1].

α-Glucosidase-IN-16 is a highly effective and orally bioavailable inhibitor of α-glucosidase, displaying a remarkable IC50 value of 3.28 μM. This compound significantly decreases blood glucose levels in Streptozotocin-induced diabetic rats and exhibits noteworthy antidiabetic activity [1].

α-Glucosidase-IN-2 (compound 5d) is a potent α-glucosidase inhibitor with an inhibitory concentration (IC50) of 9.48 μM, functioning as an antidiabetic agent [1].

α-Glucosidase-IN-20 (Compound 3B) is a highly effective, orally active α-glucosidase inhibitor with potent anti-diabetic properties, evidenced by an IC50 value of 3.01 μM [1].

α-Glucosidase-IN-15 (Compound 14B) exhibits potent α-glucosidase inhibitory activity with an IC50 value of 3.34 μM and possesses antidiabetic properties [1].

α-Glucosidase-IN-18 (7B) is an orally active α-glucosidase inhibitor with an IC50 value of 3.96 μM, exhibiting antidiabetic properties [1].

α-Amylase/α-Glucosidase-IN-2 (compound 5) exhibits strong inhibition of α-amylase and α-glucosidase enzymes, with IC50 values of 13.02 μM and 13.09 μM, respectively, showing promise for investigating diabetic complications [1].

α-Glucosidase-IN-21 (Compound 2B) is a highly potent, orally bioavailable α-glucosidase inhibitor with an IC50 value of 2.62 μM, demonstrating remarkable anti-diabetic properties [1].

α-Glucosidase-IN-11 is a highly permeable competitive inhibitor of α-glucosidase (IC50: 0.56 μM) that binds to the Trp residue in α-glucosidase, affecting protein folding and regulating blood glucose levels. [Topoisomerase II]

Alpha-Glucosidase-IN-19 (Compound 6B) is an orally active alpha-glucosidase inhibitor (IC50: 3.63 μM) with antidiabetic effects.

α-Glucosidase-IN-17 (Compound 12B) is a potent, orally active α-glucosidase inhibitor with antidiabetic activity, demonstrating an inhibitory concentration (IC50) of 3.79 μM [1].

α-Glucosidase-IN-10 (compound 13) is a potent α-glucosidase inhibitor with an IC50 of 92.7 μM, useful for studying type II diabetes.

α-Glucosidase-IN-6 is a competitive inhibitor of α-glucosidase (IC50: 5.69 μM) and exhibits potential for anti-diabetic studies.

α-Glucosidase-IN-13 is an inhibitor of α-glucosidase (IC50: 5.69 μM).

α-Glucosidase-IN-14 is a potent inhibitor of α-glucosidase (IC50: 5.22 μM).

α-Glucosidase-IN-12 is a potent inhibitor of α-glucosidase (IC50: 10.20 μM).

α-Glucosidase-IN-3, an oleanolic acid oxime ester derivative, targets α-glucosidase and α-amylase with an IC50 value of 0.35 μM for α-glucosidase.

α-Glucosidase-IN-22 is a selective inhibitor of α-glucosidase (IC50=0.64 μM). α-Glucosidase-IN-22 has antidiabetic activity and has potential in type 2 diabetes (T2DM) studies.

α-Glucosidase-IN-24 (Compound 13), an α-Glucosidase inhibitor derived from Swertia kouitchensis [1], exhibits an IC50 value of 451 μM.